| Literature DB >> 35527877 |
Alisha Prasad1, Ardalan Chaichi1, D Parker Kelley2, Joseph Francis2, Manas Ranjan Gartia1.
Abstract
Posttraumatic stress disorder (PTSD) is a trauma and stressor related psychiatric disorder associated with structural, metabolic, and molecular alternations in several brain regions including diverse cortical areas, neuroendocrine regions, the striatum, dopaminergic, adrenergic and serotonergic pathways, and the limbic system. We are in critical need of novel therapeutics and biomarkers for PTSD and a deep understanding of cutting edge imaging and spectroscopy methods is necessary for the development of promising new approaches to better diagnose and treat the disorder. According to the Diagnostic and Statistical Manual of Mental Disorders (DSM-V) criterion, all forms of traumatic stress-induced disorder are considered acute stress disorder for the first month following the stressor. Only after symptoms do not remit for one month can the disorder be deemed PTSD. It would be particularly useful to differentiate between acute stress disorder and PTSD during the one month waiting period so that more intensive treatments can be applied early on to patients with a high likelihood of developing PTSD. This would potentially enhance treatment outcomes and/or prevent the development of PTSD. Comprehension of the qualities and limitations of currently applied methods as well as the novel emerging techniques provide invaluable knowledge for fast paced development. Conventional methods of studying PTSD have proven to be insufficient for diagnosis, measurement of treatment efficacy, and monitoring disease progression. As the field currently stands, there is no diagnostic biomarker available for any psychiatric disease, PTSD included. Currently, emerging and available technologies are not utilized to their full capacity and in appropriate experimental designs for the most fruitful possible studies in this area. Therefore, there is an apparent need for improved methods in PTSD research. This review demonstrates the current state of the literature in PTSD, including molecular, cellular, and behavioral indicators, possible biomarkers and clinical and pre-clinical imaging techniques relevant to PTSD, and through this, elucidate the void of current practical imaging and spectroscopy methods that provide true biomarkers for the disorder and the significance of devising new techniques for future investigations. We are unlikely to develop a single biomarker for any psychiatric disorder however. As psychiatric disorders are incomparably complex compared to other medical diagnoses, its most likely that transcriptomic, metabolomic and structural and connectomic imaging data will have to be analyzed in concert in order to produce a dependable non-behavioral marker of PTSD. This can explain the necessity of bridging conventional approaches to novel technologies in order to create a framework for further discoveries in the treatment of PTSD. This journal is © The Royal Society of Chemistry.Entities:
Year: 2019 PMID: 35527877 PMCID: PMC9069787 DOI: 10.1039/c9ra03562a
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 4.036
Fig. 1Schematic showing the organization and highlights of the review.
Fig. 2Different biomarkers of PTSD. HPA: hypothalamic pituitary adrenal; SAM: Synergistic Activation Mediator; ACTH: adrenocorticotropic hormone; CRF: corticotropin hormone releasing factor; GCR/GR: glucocorticoid receptor; BDNF: brain-derived neurotrophic factor; GABA: Gamma-Aminobutyric Acid; FKBP5 (protein); SERT: serotonin transporter or 5-HTT; DAT: dopamine transporter gene; rRNA: ribosomal ribonucleic acid; ApoE4: apolipoprotein E; H3K27: trimethylated histone H3 lysine 4 amino acid; GFAP: glial fibrillary acidic protein; IL: interleukin; TNF: tumor necrosis factor I; NK: Natural Killer cells; Th: T-helper cells.
Fig. 3Epigenetic considerations. (a) Regions of brain involved in PTSD. Reproduced with permission from ref. 20. Copyright 2017, Society of Biological Psychiatry. (b) Mechanism of action of PTSD. Reproduced with permission from ref. 23. Copyright 2013, Raabe and Spengler. (c) Glucocorticoid sensitivity at pre- and post-treatment depending on GR BCLI polymorphism genotype (CG/GC or CC). Data were adjusted for age, gender and body mass index and are represented as mean ± SEM. Statistical significance was set at p < 0.05. Reproduced with permission from ref. 26. Copyright 2014, Published by the Royal Society. (d) Correlations of DNA methylation with gene expression. The bar graph shows the percent of CpGs with positive vs. negative correlations with gene expression. Reproduced with permission from ref. 31. Copyright 2013, National Academy of Sciences.
Summary of main findings in PTSD imaging along with the contrast agents used for the studya
| Technique | Contrast agent | Main findings | Sample size ( | References | ||
|---|---|---|---|---|---|---|
| Measure | Change | Brain region | ||||
| SPECT | HMPAO | rCBF | ↑ | Right hemisphere | 47 |
|
| HMPAO | rCBF | ↓ | Medial frontal gyrus | 30 |
| |
| rCBF | ↑ | Right cuneus | 30 |
| ||
| HMPAO | rCBF | ↑ | Cerebellum | |||
| ↓ | Right precentral, superior temporal, and fusiform gyri | 38 |
| |||
| HMPAO | rCBF | ↑ | Left hemisphere | 16 |
| |
| HMPAO | rCBF | ↑ | Prefrontal cortex | 24 |
| |
| HMPAO | rCBF | ↑ | Left amygdala, left nucleus accumbens | 28 |
| |
| HMPAO | rCBF | ↓ | Superior frontal cortex, right caudate | 31 |
| |
| [123I] Iomazenil | BZR | = | No difference in BZR levels between control and PTSD patient groups | 38 |
| |
| [123I] Iomazenil | BZR | ↓ | Prefrontal cortex | 26 |
| |
| HMPAO | rCBF | ↑ | Hippocampus, parahippocampus, amygdala | |||
| rCBF | ↓ | Dorsolateral prefrontal cortex (PFC) | 69 |
| ||
| HMPAO | rCBF | ↑ | Bilateral AC/PC, right temporal and parietal, right caudate/putamen, and left orbital and hippocampal | 25 |
| |
| HMPAO | rCBF | ↑ | Limbic | 87 |
| |
| HMPAO | rCBF | ↑ | Right superior parietal lobe | 38 |
| |
| rCBF | ↓ | Right thalamus | 38 |
| ||
| PET | [15O] H2O | rCBF | ↓ | mPFC/ACC | ||
| = | Amygdala | 29 |
| |||
| [O15] CO2 | rCBF | ↑ | Hippocampus, amygdala | 16 |
| |
| [15O] H2O | rCBF | ↓ | Hippocampus, mPFC/ACC, mPFC/OFC | 21 |
| |
| [15O] H2O | rCBF | ↓ | Hippocampus, mPFC/OFC | 22 |
| |
| 15Q-Butanol | rCBF | ↑ | Parahippocampus, amygdala | |||
| rCBF | ↓ | mPFC/ACC | 13 |
| ||
| [15O] H2O | rCBF | ↑ | Parahippocampus | 22 | ||
| rCBF | ↓ | mPFC/ACC |
| |||
| [15O] H2O | rCBF | ↓ | Hippocampus, mPFC/ACC, mPFC/OFC | |||
| rCBF | ↑ | Parahippocampus | 20 |
| ||
| [15O] CO2 | rCBF | ↑ | Parahippocampus, mPFC/OFC | |||
| rCBF | ↓ | mPFC/ACC | 16 |
| ||
| [15O] CO2 | rCBF | ↑ | Amygdala | 14 |
| |
| [18F] FDG | GMB | ↓ | Hippocampus, mPFC/OFC | |||
| = | Parahippocampus, amygdala, mPFC/ACC | 20 |
| |||
| [15O] H2O | rCBF | = | mPFC/ACC | 16 |
| |
| [15O] H2O | rCBF | ↑ | mPFC/OFC | 13 |
| |
| fMRI | BOLD | ↑ | Amygdala | |||
| ↓ | mPFC/ACC | 26 |
| |||
| BOLD | ↑ | Amygdala | 32 |
| ||
| BOLD | ↑ | Parahippocampus | ||||
| ↓ | mPFC/ACC | |||||
| = | Amygdala | 11 |
| |||
| BOLD | ↑ | Parahippocampus, amygdala | ||||
| ↓ | mPFC/OFC | 12 |
| |||
| BOLD | ↓ | Thalamus | 24 |
| ||
| BOLD | ↑ | Amygdala | 21 |
| ||
| BOLD | ↓ | Parahippocampus, thalamus, mPFC/ACC | 20 |
| ||
| BOLD | ↓ | Parahippocampus | ||||
| ↑ | mPFC/ACC | |||||
| = | Thalamus | 17 |
| |||
| BOLD | ↓ | Hippocampus, parahippocampus | ||||
| ↑ | Thalamus, mPFC/ACC | 16 |
| |||
| BOLD | ↓ | mPFC/ACC, mPFC/OFC, thalamus | ||||
| = | Amygdala | 18 |
| |||
| BOLD | ↑ | Amygdala | ||||
| = | mPFC/ACC | 16 |
| |||
HMPAO: 99mTc hexamethyl-propyleneamine oxime; rCBF: regional cerebral blood flow; BZR: benzodiazepine receptors; AC: anterior cingulate; PC: posterior cingulate; mPFC/ACC: medial prefrontal cortex/anterior cingulated cortex; OFC: orbitofrontal cortex; FDG: fluorodeoxyglucose; GMB: glucose metabolism; BOLD: blood oxygen level-dependent signal; = : no change in activity; ↑: increase in activity; ↓: decrease in activity.
Summary of imaging modalitiesa
| Technique | Depth | Spatial resolution | Temporal resolution | Strength | Limitation | Clinical use | Physical principle |
|---|---|---|---|---|---|---|---|
| SPECT | Whole brain | 1–5 mm | Minutes | Non-invasive, lower cost compared to PET, longer half-life (∼6 h) for radio tracers, allow longer imaging time, sensitivity: 10−10 to 10−11 mol L−1 | Poor spatial resolution, radiation dose exposure, limited number of radionuclides (99mTc, 123I) | Yes | Low-energy γ-rays |
| PET | Whole brain | 1–5 mm | Seconds to minutes | High sensitivity compared to SPECT, radionuclides used in PET (11C, 13N, 8F) are abundant in the body and can be tailored for endogenous biomolecules such as carbohydrates, fats, nucleic acids and proteins, sensitivity: 10−11 to 10−12 mol L−1 | Short half-life (∼75 s) for the radio tracers and hence must be produced onsite before imaging, high-cost compared to SPECT, limited imaging time window | Yes | High-energy γ-rays |
| CT | Whole brain | 50 μm | Minutes | High spatial resolution, fast and cross-sectional images of the brain, sensitivity: 10−6 mol L−1 | Structure of the brain, not its function, low contrast | Yes | X-rays |
| fMRI | Whole brain | 25–100 μm | Minutes to hours | No radiation, structural and functional data, high spatial resolution, greater contrast for soft tissues, imaging agents with lower toxicity, sensitivity: 10−3 to 10−5 mol L−1 | High cost, long scanning time, sensitive to motion artifacts, relatively low sensitivity and low contrast | Yes | Radio waves |
| Ultrasound | 1-5 cm | 50–500 μm | Seconds to minutes | Low cost, no radiation, high speed, portable, sensitivity with microbubbles: 10−12 mol L−1 | Low contrast | Yes | High frequency sound waves |
| EEG | Scalp | 5–10 cm | Millisecond | Inexpensive, portable, high temporal resolution, electrical activity of brain | Low spatial resolution, prone to error due to environmental noise, localization of signal is difficult | Yes | Electrical |
| MEG | Scalp | 1-5 mm | Millisecond | High temporal resolution | Expensive | Yes | Electromagnetic |
| fNIR | < 1 cm | 2–3 mm | Seconds to minutes | No radiation, inexpensive, sensitivity: 10−9 to 10−12 mol L−1 | Scattering due to tissues may be a problem, low penetration depth | Preclinical | Near-infrared light |
| Photoacoustic | 0.6–5 cm | 10 μm to 1 mm | Seconds to minutes | No radiation, label-free, high spatial resolution and low cost compared to CT/PET, sensitivity: 10−6 to 10−12 mol L−1 | Distortion of acoustic signal due to skull, temperature dependent signal, weak absorption at shorter wavelengths | Preclinical | Pulsed laser and sound wave |
| VSDI | 1 mm | 50 μm | Millisecond | High temporal resolution | Invasive, prone to photobleaching of dye, toxic to cells | Preclinical | Voltage sensitive dye |
| Bioluminescence | 1-2 cm | 3–5 mm | Seconds-Minutes | No radiation, high sensitivity, inexpensive, sensitivity: 10−15 to 10−17 mol L−1 | Scattering due to tissues may be a problem, spatial resolution is low | Preclinical | Visible light |
| LSCI | 0.5–1 mm | 10 μm | Microseconds | Label-free, high temporal resolution | Invasive | Preclinical | Visible and near infrared laser |
| Two-photon | 1 mm | 1 μm | Microseconds | High spatial resolution | Invasive, photobleaching issues with dyes, scattering due to tissues | Preclinical | Infrared laser |
| FTIR | <1 cm | 5–12 μm | Seconds to minutes | Label-free method, short imaging time | High attenuation in liquid environment, difficult to distinguish closely related molecular structures | Preclinical | Infrared light |
| Raman | 5 mm | <1 μm | Minutes to days | Label-free analysis, high spatial resolution, can work with liquid environment | Complex statistical analysis may be required to separate analytes, long imaging time required for imaging large area at high resolution | Preclinical | Visible and near infrared laser |
SPECT: Single Photon Emission Computed Tomography; PET: Positron Emission Tomography; CT: Computed Tomography; fMRI: functional Magnetic Resonance Imaging; EEG: electroencephalogram; MEG: magnetoencephalography; fNIR: functional Near-Infrared Imaging; VSDI: Voltage-Sensitive Dye Imaging; LSCI: Laser Speckle Contrast Imaging; FTIR: Fourier Transform Infrared Microscopy.
Fig. 4(a) AAV vector-mediated expression of foreign gene in mouse brain (left). Immunostained cells for AAV-hαSyn-injected mice (right). Reproduced with permission from ref. 93. Copyright 2012, Yasuda, Nakata, and Mochizuki. (b) FTIR spectra, a: core of an LB, b: halo of an LB, and c: normal brain tissue (top). FTIR imaging of brain showing total amount of proteins (from left to right, bottom). The color bar indicates low (blue) to high (red) contents. The area in the visible image was scanned with 5 μm steps (16 × 8 pixels = 80 × 40 μm2). Scale bar, 10 μm. Reproduced with permission from ref. 91. Copyright 2015, Macmillan Publishers Limited. (c) Secondary derivative infrared spectra of damaged and injured axons. Reproduced with permission from ref. 95. Copyright 2017, Zhang, Huang, Wang, and Dong. (d) TAI in the CC detected by b-APP staining following impact acceleration of TBI(top). A: No β-APP staining, B: β-APP-stained axons at 12 h, C: 24 h, D: 72 h (scale bar = 50 μm). Superimposition of all normalized FTIR spectra collected in the CC of rats at different post-injury groups (bottom). Reproduced with permission from ref. 94. Copyright 2015, John Wiley & Sons.
Fig. 5(a) fNIRS designed probe. Location of sources (red circles) and detectors (blue circles) on the cap (top left). Sensitivity profile for the probe. The channel numbers are in yellow. The color scale spans the sensitivity logarithmically from 0.01 (blue) to 1 (red). Group mean HbO and HbR hemodynamic responses overlayed over the brain surface for: encoding (bottom left) and recalling (bottom right) of novel and same faces. The displayed concentration changed was averaged from t = 25 to 50 s. The color bar indicates the scale of the concentration change in μM units. Reproduced with permission from ref. 101. Copyright 2017, Nature Publishing Group. (b) Configuration (top) of the fNIRS probe. Red circles represent light sources, blue squares represent detectors, and green lines represent the nearest source–detector pairs (channels) to measure the brain activities. Mean task-evoked prefrontal hemodynamic responses in the: control group (middle) forward task (middle left) and backward task (middle right), PTSD group (bottom) forward task (bottom left) and backward task (bottom right). In both panels, the solid lines represent the mean time courses of HbO2, the dotted lines represent the mean time courses of Hb, the shaded regions represent the standard errors, the * symbols indicate the period of significant HbO2 changes (one-sample t-test, p < 0.01) from the baseline, and the gray bars in the bottom indicate the three phases of the task. It is noted that the actual retrieval time was slightly variable among participants. Therefore, the retrieval phases labeled in both panels are schematic and approximate. Reproduced with permission from ref. 104. Copyright 2014, Tian et al. Published by Elsevier. (c) Handheld NIR device. Bluetooth equipped Full device (part 1) intra (part 2) and extra (part 3) – axial hemorrhagic haematomas acquisition. Reproduced with permission from ref. 105. Copyright 2010, Taylor & Francis.
Fig. 6Raman spectroscopy to detect tissue biochemistry. (a) Bright field microscopy of murine brains at 7th day and control (inset photographs show sample preparation). Average Raman spectra shown were acquired from the areas indicated in matching colors in the photos. CL = contralateral; ID = ipsilateral distant from contusion core; PC = pericontusional tissue; and CC = contusion core. Spectra were acquired at 785 nm, with 1 s exposure and 10 accumulations; the average is performed over 30 separate spatial points (bottom). (b) Raman spectral of the cholesterol, cholesteryl nonanoate, cholesteryl oleyl carbonate, and intralipid (no structure was shown as mixed lipids). Protein albumin was shown for reference. Spectra were acquired at 785 nm, with 1 s exposure and 10 accumulations at 175 mw; the average is performed over 10 separate spatial points. Reproduced with permission from ref. 109. Copyright 2017, Published by The Royal Society of Chemistry. (c) Image of a handheld contact Raman spectroscopy probe. Reproduced with permission from ref. 110. Copyright 2015, American Association for the Advancement of Science.
Fig. 7(a) Representative in vivo near-infrared fluorescence assortments of PSS-794, Tracer-794, and Annexin-Vivo 750 accumulations in a brain cryoinjury mouse model. A precooled metal cylinder was applied to the head of each mouse for 60 s followed by intravenous injection of either PSS794 (3.0 mg kg−1), Tracer-794 (3.0 mg kg−1), or Annexin-Vivo 750. Images were acquired at the indicated time points after probe injection. N = 5. (left) Multicolor fluorescence ex vivo imaging of cell death and blood brain-barrier disruption in cryoinjured brains (right). Reproduced with permission from ref. 113. Copyright 2012, American Chemical Society. (b) Confocal images of vessel painted vasculature at the perilesional region for Sham and TBI. Cal bar = 200 μm (top). Classical vascular analysis using AngioTool imaging software. Axial vessels are displayed (red) and junctions (blue). Reproduced with permission from ref. 114. Copyright 2017, Nature Publishing Group. (c) Two-photon Fluorescence Micro endoscope. Computer aided design (CAD) (part 1), top view of entire setup (part 2), internal components (part 3), mechanism of light collection (part 4). Reproduced with permission from ref. 115. Copyright 2005, The Optical Society. (d) Image of a 3 mm outer diameter multiphoton endoscope. Reproduced with permission from ref. 116. Copyright 2011, National Academy of Sciences.
Fig. 8Other optical imaging techniques. (a) Schematics of Photoacoustic Tomography (PAT). Reproduced with permission from ref. 117. Copyright 2014, National Academy of Sciences. (b) Schematics of the assembled Laser speckle contrast imaging (LSCI) with microscope showing incident and reflected light paths in blue and green (left), and imaging of free moving mice (right). Reproduced with permission from ref. 118. Copyright 2009, Elsevier B.V. (c) Demonstration of voltage sensitive dye imaging (VSDi) system. Schematics shows localization of dye in the membranes and a VSDi optical image acquired from the assembled setup. Reproduced with permission from ref. 119. Copyright 2013, Elsevier B.V.
Fig. 9Comparison of temporal and spatial resolution for conventional and emerging methods.